申请人:Pfizer Inc.
公开号:US04602016A1
公开(公告)日:1986-07-22
N-(mono or disubstituted phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine, and the vascular complications of diabetes.
N-(单取代或双取代苯氧烷基)咪唑及其药用可接受的酸盐能够选择性地抑制血栓素合成酶酶的作用,而不显著抑制前列环素合成酶或环氧化酶酶的作用,因此在缺血性心脏病、中风、短暂性缺血发作、血栓形成、偏头痛以及糖尿病的血管并发症治疗中是有用的。